OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 151 filers reported holding OCULAR THERAPEUTIX INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,793 | -86.9% | 21,590 | -78.4% | 0.01% | -90.2% |
| Q2 2023 | $516,000 | -51.0% | 100,000 | -50.0% | 0.08% | -65.7% |
| Q1 2023 | $1,054,000 | +87.5% | 200,000 | 0.0% | 0.24% | +75.7% |
| Q4 2022 | $562,000 | -48.9% | 200,000 | -24.5% | 0.14% | -37.9% |
| Q3 2022 | $1,099,000 | +647.6% | 265,000 | +793.9% | 0.22% | +1052.6% |
| Q1 2022 | $147,000 | -23.0% | 29,644 | +7.6% | 0.02% | -32.1% |
| Q4 2021 | $191,000 | -97.5% | 27,551 | -96.4% | 0.03% | -94.8% |
| Q3 2021 | $7,707,000 | -51.5% | 770,751 | -31.2% | 0.54% | -57.8% |
| Q2 2021 | $15,879,000 | +42.0% | 1,119,573 | +64.2% | 1.28% | +240.6% |
| Q1 2021 | $11,186,000 | -45.8% | 681,673 | -31.6% | 0.38% | -58.6% |
| Q4 2020 | $20,632,000 | +58.0% | 996,673 | -41.9% | 0.91% | -3.7% |
| Q3 2020 | $13,061,000 | -23.7% | 1,716,293 | -16.5% | 0.94% | -30.7% |
| Q2 2020 | $17,126,000 | +121.9% | 2,055,977 | +31.9% | 1.36% | +135.0% |
| Q1 2020 | $7,717,000 | +176.0% | 1,558,936 | +120.3% | 0.58% | +28.0% |
| Q4 2019 | $2,796,000 | – | 707,659 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |